About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.

Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma

Clinicaltrials.gov identifier NCT03927274

Recruitment Status Recruiting

First Posted April 25, 2019

Last update posted May 14, 2021

Study Description

Brief summary:

The purpose of this study is to determine if treatment with Topotecan by an alternative method, delivering topotecan directly into brain tumors, is safe and well tolerated.

  • Condition or Disease:Glioma of Brain
  • Intervention/Treatment: Drug: Topotecan
  • Phase: Early Phase 1
Detailed Description

N/A

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 5 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: A Study of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy
  • Actual Study Start Date: June 2019
  • Estimated Primary Completion Date: December 2021
  • Estimated Study Completion Date: December 2022
Arms and interventions
Arm Intervention/treatment
Experimental: Cleveland Multiport Catheter (CMC) + Topotecan
For predominantly enhanced tumors with volume of 8 cc or less, only 1 Cleveland Multiport Catheter (CMC) will be placed and convection-enhanced delivery (CED) will be performed over a 4-hour period within an MRI scanner, with the goal of complete tumor coverage (as evidenced by tracer distribution on MRI). The initial rate will be 1.20 ml/hour (5.0 microliters/minute/microcatheter) and infusion will be monitored by intermittent MRI imaging. The rate may be adjusted upwards during the infusion, in the event of incomplete tumor coverage, or downwards, if new mass effect is apparent. Following completion of the 4-hour infusion, the CMC will be removed. The initial rate for each subsequent patient may be adjusted upwards in increments of up to 5 microliters/minute/microcatheter based upon the tumor coverage and safety characteristics of the previously treated patients.
Drug: Topotecan
Intratumorally-administered topotecan using convection-enhanced delivery (CED) in patients with suspected recurrent/progressive High Grade Glioma (HGG) requiring stereotactic biopsy and is focused on investigating topotecan brain tissue distribution and determining the safety, toxicity, and tolerability of intratumorally-administered topotecan.
Outcome Measures
  • Primary Outcome Measures: 1. Distribution of topotecan in tumor tissue [ Time Frame: Treatment day 1 ]
    The spatial distribution of intratumorally-administered topotecan will be determined using a gadolinium-based contrast agent, volumetric magnetic resonance imaging, and three-dimensional image reconstruction.
  • Secondary Outcome Measures: 1. Number of Adverse Events (AEs) experienced by participants [ Time Frame: Up to 48 weeks ]
  • 2. Extent of topotecan backflow [ Time Frame: Treatment day 1 ]
    Investigate the extent to which backflow may be observed on MRI during CED-mediated delivery of topotecan
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Histologically confirmed diagnosis of supratentorial WHO Grade III or IV Glioma (High
Grade Glioma) that has undergone surgical biopsy or resection followed by adjuvant
chemoradiotherapy, that has evidence of recurrence or progression based on imaging
studies and a stereotactic biopsy is indicated for confirmation of
recurrence/progression.

- 18 years of age or older

- Karnofsky Performance Status 70-100;

- MRI demonstration of a stereotactically accessible enhancing or predominantly non-
enhancing mass that does not require resection to relieve clinically significant mass
effect;

- Participant understands the procedures and agrees to comply with the study
requirements by providing written informed consent

- Adequate organ function as indicated in protocol

Exclusion Criteria:

- Participant is mentally or legally incapacitated at the time of the study;

- Known HIV(+) or has been diagnosed with AIDS

- Participation in another investigational drug study in the prior 4 weeks

- Positive pregnancy test in a female

- Patient, in the opinion of the investigator, is likely to be poorly compliant.

- Diffuse subependymal or Cerebral Spinal Fluid (CSF) disease

- Tumors involving the cerebellum

- Tumor enhancement involving both hemispheres

- Active infection requiring treatment

- Unexplained febrile illness

- Radiation or chemotherapy within 4 weeks of enrollment

- Systemic diseases associated with unacceptable anesthesia or operative risk

- Inability to undergo magnetic resonance imaging (MRI)

Contacts and Locations
Contacts

Contact: Jerry Owens 813-745-1656 Jerry.Owens@Moffitt.org

Locations

United States, Florida
Moffitt Cancer Center
Tampa

Sponsors and Collaborators

H. Lee Moffitt Cancer Center and Research Institute

Investigators

Principal Investigator: Michael Vogelbaum, M.D, PhD Moffitt Cancer Center

More Information
  • Responsible Party: H. Lee Moffitt Cancer Center and Research Institute
  • ClinicalTrials.gov Identifier: NCT03927274 History of Changes
  • Other Study ID Numbers: MCC-19970
  • First Posted: April 25, 2019 Key Record Dates
  • Last Update Posted: May 14, 2021
  • Last Verified: May 2021
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by H. Lee Moffitt Cancer Center and Research Institute: Glioma
    Brain Tumor
    High Grade Glioma
  • Additional relevant MeSH terms: Glioma